CClinicalTrials.gg
CompletedNCT05819242Updated Oct 6, 2023

The Reliability And Validity Of A Smartphone App

An observational study in Rheumatoid Arthritis and Carpal Tunnel Syndrome, sponsored by Kirsehir Ahi Evran Universitesi. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-06.

Sponsored by Kirsehir Ahi Evran Universitesi · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
64
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this observational study is to validate a smartphone app called Angulus. The main question it aims to answer is:

  • Is an Angulus App valid and reliable system for masuring hand and wrist range of motion?

Participants will be evaluated by goniometers which is a gold standart for range of motion assessment.

02

Conditions studied

  • Rheumatoid Arthritis
  • Carpal Tunnel Syndrome

Keywords

  • reliability
  • validity
  • range of motion
03

In context

Carpal Tunnel Syndrome

589 studies on the registry are indexed under Carpal Tunnel Syndrome; 139 are open to participants now.

This study's enrollment of 64 is below the median of 90 across 127 observational studies indexed under Carpal Tunnel Syndrome.

Browse Carpal Tunnel Syndrome studies →

Lead sponsor

Kirsehir Ahi Evran Universitesi is the lead sponsor of 133 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy

Inclusion criteria

  • a history of previous traumatic hand or wrist injury in the upper extremity,
  • pain in the hand and wrist during evaluation
  • orthopedic, neurologic, or rheumatologic disease

Exclusion criteria

Exclusion Criteria:

  • not to understand the command that the therapist give
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
64 participants (actual)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Healthy Adults

    Diagnostic Test: Angulus

  • Rheumatoid Arthritis

    Diagnostic Test: Angulus

  • Carpal Tunnel Syndrome

    Diagnostic Test: Angulus

Interventions

  • Diagnostic testAngulus

    Smartphone app

06

What researchers measure

Primary outcomes

  1. Range of Motions

    Time frame: 15 weeks

07

Study locations

1 site
  • Ahi Evran University
    Kırşehir, Turkey
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05819242
Lead sponsor
Kirsehir Ahi Evran Universitesi
Responsible party
Ömer Faruk ÖZÇELEP (Researcher, Kirsehir Ahi Evran Universitesi) — Principal investigator
First posted
Apr 19, 2023
Start date
Apr 7, 2023
Primary completion
Oct 5, 2023
Completion
Oct 5, 2023
Last update
Oct 6, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion